Publication in refereed journal
香港中文大学研究人员 ( 现职)
| 莫树锦教授 (肿瘤学系) |
| 马碧如教授 (肿瘤学系) |
全文
| 数位物件识别号 (DOI) http://dx.doi.org/10.1016/S1470-2045(09)70160-3 |
引用次数
Web of Sciencehttp://aims.cuhk.edu.hk/converis/portal/Publication/73WOS source URL
其它资讯
摘要Population-based differences in toxicity and clinical outcome following treatment with anticancer drugs have an important effect on oncology practice and drug development. These differences arise from complex interactions between biological and environmental factors, which include genetic diversity affecting drug metabolism and the expression of drug targets, variations in tumour biology and host physiology, socioeconomic disparities, and regional preferences in treatment standards. Some well-known examples include the high prevalence of activating epidermal growth factor receptor (EGFR) mutations in pulmonary adenocarcinoma among northeast (China, Japan, Korea) and parts of southeast Asia (excluding India) non-smokers, which predict sensitivity to EGFR kinase inhibitors, and the sharp contrast between Japan and the west in the management and survival outcome of gastric cancer. This review is a critical overview of population-based differences in the four most prevalent cancers in the world: lung, breast, colorectal, and stomach cancer. Particular attention is given to the clinical relevance of such knowledge in terms of the individualisation of drug therapy and in the design of clinical trials.
着者Ma BBY, Hui EP, Mok TSK
期刊名称Lancet Oncology
出版年份2010
月份1
日期1
卷号11
期次1
出版社ELSEVIER SCIENCE INC
页次75 - 84
国际标準期刊号1470-2045
电子国际标準期刊号1474-5488
语言英式英语
Web of Science 学科类别Oncology; ONCOLOGY
